Simvastatin reprograms lipid metabolism in B16.F10 melanoma cells to favor an early resistant phenotype Authors: Giorgiana-Gabriela Negrea, Loredana Balacescu, Ilie Ovidiu Pavel, Alina Sesarman, Manuela Banciu Published: 2026 ABSTRACT Our previous studies demonstrated that simvastatin (SIM) inhibited B16.F10 murine melanoma cell proliferation in vivo and in vitro via strong suppressing the production of subunit α of hypoxia inducible factor 1 (HIF-1) (HIF-1 α)—a key regulator of cancer cell adaptation to hypoxia. However, beyond its known role in hypoxia, normoxic expression of HIF-1α in melanoma has been linked to increased cancer cell aggressiveness, underscoring its broader impact on tumor biology. Since the translation of HIF-1α is modulated by Akt, SIM effects on both regulatory factors in relation to cancer cell metabolism under normoxia were investigated. SIM- induced metabolic changes were analyzed at mRNA and at protein level. Our data suggested that SIM reprogrammed glucose metabolism to ensure replenishment of the tricarboxylic acid (TCA) cycle, favoring its biosynthetic role over its energy role. This shift supported lipid-derived signaling molecules synthesis including isoprenoids and prostaglandins, favoring traits associated with cell survival and drug tolerance. Additional validation in human A375 melanoma cells demonstrated comparable antiproliferative effects of SIM, while in silico cross-species transcriptomic analysis revealed shared suppression of cell-cycle-related programs together with context-dependent metabolic responses. Our results have important clinical implications, as they emphasize the potential of targeting key lipid metabolic pathways to overcome the adaptive mechanisms associated with normoxic HIF-1α expression. Thus, our data offer promise for novel combination therapies which disrupt the metabolic plasticity of melanoma, to ultimately improve therapeutic outcomes.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-52873-1. Introduction Statins show disparate effects on cancer cells depending on concentration. While high-dose statins demonstrate promise in suppressing cancer progression, low-dose statins may paradoxically promote pro-survival or pro-aggressive behavior in cancer cells1,2. Statins antitumor effects are achieved when administrated in doses 100–500 times higher than those needed to lower cholesterol biosynthesis3–7. Thus, our data proved that simvastatin (SIM), a lipophilic statin strongly inhibited B16.F10 murine melanoma cell proliferation in vivo and in vitro via strong suppression of the expression of subunit α of hypoxia inducible factor 1 (HIF-1 α)3,5,7 under hypoxic5 as well as normoxic conditions3. Moreover, one of the hallmarks of cancer cells remains the HIF-1-regulated metabolism reprogramming which supports cell growth, survival, metastasis, and resistance to therapies8–12. Notably, hypoxia-stabilized expression of HIF-1α is essential for regulation of multiple cancer-related metabolic pathways such as activation of metabolic genes involved in increasing glycolysis, FAS, pentose phosphate pathway (PPP), and nucleotide biogenesis13–16. Thus, HIF-1 suppresses pyruvate dehydrogenase (PDH), via activation of PDH kinase-1 (PDK-1) expression, resulting in inhibition of the mitochondrial metabolism (tricarboxylic acid (TCA) cycle and oxidative phosphorylation (OXPHOS)), which ensures cancer cell survival under hypoxia13–16. Besides the role of HIF-1 to ensure tumor survival and progression under hypoxic stress conditions, normoxic expression of HIF-1α in melanoma tumors is associated with increased aggressiveness of these cancer cells3,17,18. In tight connection with our earlier observation about the suppressive effect of SIM on normoxic HIF-1α expression3, we aimed to explore how inhibition of the constitutive level of this transcription factor could affect cancer cell metabolism. Thus, RNA-seq revealed expression changes induced by SIM in genes involved in energy and biosynthesis metabolic pathways. To validate these data, we evaluated the expression and catalytic activities of several proteins such as fatty acid synthase (FASN), stearyl-CoA desaturase 1 (SCD1) and phosphofructokinase 1 (PFK1). Our results indicated that low-dose SIM treatment (at IC50 value) influenced B16.F10 melanoma cells metabolism to adapt and become resistant to the treatment. The metabolism was redirected towards the synthesis of FA, mainly favoring unsaturated fatty acids (UFAs) abundance. This metabolic shift could potentially result in elevated prostaglandin synthesis and bioactive lipids with various signaling roles in the cancer progression19–24. To provide a broader framework for interpreting the relevance of our findings in murine cells, we performed a complementary analysis in human A375 melanoma cells together with an in silico cross-species transcriptomic comparison. These analyses showed that SIM induced similar antiproliferative effects and partially preserved the transcriptional changes observed in B16.F10 cells, in human A375 melanoma cells as well, despite differences in the concentrations used. However, further studies are needed to determine whether these pathways are functionally engaged following SIM treatment. Results SIM hindered key regulatory molecules of cancer cell metabolism reprogramming Based on our previous data that showed that 3.5 µM SIM induced inhibition of B16.F10 murine melanoma cell proliferation by 50% under normoxia3, we assessed the effects of this lipophilic statin on the production of two regulatory proteins for cancer cell aggressiveness and metabolism reprogramming: pAkt25–29 and HIF-18,30–33. Consequently, mRNA expression was assessed via RNA-seq analysis, RT-qPCR and protein levels via western blot analysis. Our data suggested no changes in the mRNA levels corresponding to both regulators, in the SIM-treated group compared to the untreated group (30). Nevertheless, SIM exerted suppressive effects on protein production for the subunit ɑ of HIF-1 (HIF-1ɑ) by 30% (p < 0.01) (Fig. 1 a,b), and significantly reduced the ratio of the active form of Akt/total Akt production by 1.4 fold (p < 0.001) (Fig. 1 c,d) in comparison with the control protein levels. These data suggested a regulatory mechanism modulated by SIM at the translational level. In tight connection with this finding, significant changes were detected in the mRNA profile for proteins involved in post-synthetic modification of both Akt, such as heat shock protein 90 (HSP90) which showed a marked reduction following treatment (300 times reduction after treatment compared to control, p < 0.05), and PTEN induced putative kinase 1 (PINK1) (by almost 2 times, p < 0.05) (53–55), as well as in HIF-1ɑ translation: eukaryotic translation initiation factor 4A1 (eIF4A1) (FR = -17.75, p < 0.05), ribosomal protein S6 kinase polypeptide 2 (Rps6kb2) (FR = -3, p < 0.05) and ribosomal protein S6 (RPS6) (FR = -1.6, p < 0.05) (Supplementary Table 1—deposited in GEO under accession GSE329678; Supplementary Fig. 1)34–36.Fig. 1Protein levels of two regulatory molecules after 3.5 µM SIM-administration in B16.F10 cells under normoxia. (a, c) Western blot images of the expression levels of HIF-1α, total Akt and pAkt. β-actin was used as loading control; (b) Percentages of the HIF-1α levels in SIM-treated cells (SIM) in comparison with the production of the same protein in control lysates (CTR); (d) The ratio of expression levels of pAkt protein of total Akt levels in comparison with the production of the same protein in control lysates (CTR). Data were expressed as mean ± SD of at least three independent measurements; * p < 0.05; *** p < 0.001. Original blots are presented in Supplementary Figs. 7–9. Protein levels of two regulatory molecules after 3.5 µM SIM-administration in B16.F10 cells under normoxia. (a, c) Western blot images of the expression levels of HIF-1α, total Akt and pAkt. β-actin was used as loading control; (b) Percentages of the HIF-1α levels in SIM-treated cells (SIM) in comparison with the production of the same protein in control lysates (CTR); (d) The ratio of expression levels of pAkt protein of total Akt levels in comparison with the production of the same protein in control lysates (CTR). Data were expressed as mean ± SD of at least three independent measurements; * p < 0.05; *** p < 0.001. Original blots are presented in Supplementary Figs. 7–9. SIM treatment altered the expression of mRNA for SREBP1 and FOXM1—two important regulators of cholesterol biosynthesis and tumor development As statins are proven to be competitive inhibitors of cholesterol biosynthesis37, as well as due to the importance of this pathway for tumor development and progression38,39 we explored the effects of SIM on the transcriptomic profile of the cholesterol biosynthesis and regulation. Our data indicated that two positive regulators of cholesterol biosynthesis, such as sterol regulatory element binding proteins (SREBP1)40, as well as of forkhead box M1 (FOXM1) factor associated with mevalonate pathway regulation, tumorigenesis and glucose metabolism41,42were significantly reduced by SIM. Moreover, insulin induced gene proteins 1 and 2 (INSIG 1 and INSIG 2), responsible for maintaining SRBEP in inactive form, were both twofold overexpressed after the same treatment43,44 (Supplementary Table 1—repository; Supplementary Fig. 2). In addition to these findings, except for the gene encoding for the rate-limiting enzyme 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMG-CR)45, transcripts of genes encoding for most enzymes of the same pathway were upregulated in response to SIM-treatment, as follows: 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (HMG-CS1, FR = 3.48; p < 0.001), squalene epoxidase (SQLE, FR = 2.38; p < 0.05), mevalonate (diphospho) decarboxylase (MVD, FR = 2.7; p < 0.01), isopentenyl-diphosphate isomerase (IDI1, FR = 3.21; p < 0.01), farnesyl diphosphate synthase (FDPS, FR = 1.95; p < 0.01), and acetyl-coenzyme A acetyl-transferase 2 (ACAT2, FR = 3.25; p < 0.01) (Supplementary Table 1 – repository). These findings are consistent with a compensatory transcriptional response to SIM exposure, where reduced expression of key regulatory molecules was counteracted by increased expression of mRNA for isoprenoid biosynthetic enzymes, supporting signaling pathways involved in melanoma cell proliferation46–48. SIM effects on transcriptomic profile of metabolism of B16.F10 melanoma cells under normoxia As SIM affected the protein synthesis of two metabolic reprogramming regulators HIF-1α and Akt, we investigated by RNA-seq the mRNA levels of genes encoding for proteins involved in several metabolic pathways controlled by these factors. To validate these data, RT-qPCR was used to assess the expression of HIF-1α, Akt and direct/indirect targets in the metabolic pathways analyzed (Supplementary Fig. 2—Mendeley Data45). We found full concordance between RT-qPCR data and RNA-Seq results in terms of both the magnitude and the direction of expression changes. For FASN, isocitrate dehydrogenase 1 (IDH1) and solute carrier family 1 glutamate transporter member 4 (SLC1A4) genes, the expression levels were slightly higher than those obtained by RNA-Seq, while the expression of all the others was comparable between the two techniques. Our data revealed a panel of 1512 out of 15,905 genes with at least 1.5 FR in expression (FDR < 0.2 and p-value < 0.05) after SIM treatment, with 816 transcripts upregulated, and 696 downregulated compared to the control group (Supplementary Table 1—repository), as being showed in Fig. 2 in the bar plot (a), the Venn diagram (b), and the Vulcano plot (c). GO functional enrichment analysis for cellular component (CC), molecular function (MF) and biological function (BP) are represented in Fig. 2 d. KEGG pathway enrichment analysis, represented in Fig. 2 e showed significantly enriched pathways in SIM-treated group compared to control and indicated that Metabolic pathways had the highest rich factor (ratio of the DEGs number in the pathway and the number of all genes annotated in the pathway) (Supplementary Table 2—deposited in GEO under accession GSE329678). DEGs analysis showed that SIM treatment might favor the transcription of genes encoding proteins which are involved in glucose, glutamine and FA transport, glycolysis, PPP, TCA cycle, OXPHOS, FAS, fatty acids elongation (FAE), and peroxisomal β-oxidation (FAO) (Figs. 2 f and 3; Table 1). In contrast, reduced expression was noticed for transcripts related to ribonucleotide synthesis, OXPHOS and mitochondrial biogenesis as showed by the clustering of DEGs in the hierarchical representation (Figs. 2 f and 3; Table 1). Namely, SIM treatment was linked to increase in the mRNA levels of genes encoding enzymes involved in glucose metabolic pathways such as glycolysis: aldolase C (AldoC) (FR = 2.06; p = 0.0027) and enolase 2 (Eno2) (FR = 1.96; p = 0.0248), as well as PPP: G6PD (FR = 1.5; p = 0.0003) and 6-phosphogluconolactonase (PGLS) (FR = 1.87; p = 0.0305) compared to the control levels (Table 1; Figs. 2 and 3). Although there were increased mRNA levels of genes encoding for proteins involved in mitochondrial metabolism, such as IDH1 and several electron transport chain (ETC) subunits, one subunit of the ETC complex I, NADH dehydrogenase: Ubiquinone Oxidoreductase Subunit B10 (Ndufb10) was downregulated (FR = -1.53; p = 0.0294) and the mitochondrial biogenesis was affected by SIM treatment (nuclear respiratory factor 1 (NRF1) downregulation; p < 0.05) (Table 1; Fig. 2 and Supplementary Fig. 3). Moreover, our data suggested that SIM administration may have favored both lipolysis and FAS as increased levels of transcripts were noted for lipolysis enzymes: adipose triglyceride lipase (ATGL) by twofold (FR = 1.92; p < 0.05), monoacylglycerol lipase (MAGL) by ninefold (FR = 9.18; p < 0.05), phospholipase D1 (PLD1) by fivefold (FR = 5.28; p = 0.017), and for FAS and FAE: solute carrier family 25 member 1 (SLC25A1) (FR = 1.96; p = 0.001) transporter of mitochondrial citrate into the cytosol (68) and ATP citrate lyase (ACLY), the enzyme responsible for linking of TCA to cytosolic FAS (FR = 1.65; p = 0.0037), FASN (FR = 1.98; p = 0.002) and elongation of long chain fatty acids family, member 6 (ELOVL6; FR = 2.02; p = 0.004). Also, SIM favored UFAs abundance by upregulating SCD1 mRNA expression by twofold (FR = 1.86; p = 0.005) (Table 1; Figs. 2 and 3). Interestingly, while mitochondrial FAO-related transcripts were almost unchanged (Supplementary Table 1—repository), SIM effect was linked to increased expression of mRNA levels of ACOX3, the rate-limiting enzyme of peroxisomal FAO45 (FR = 2.13; p = 0.0065) (Table 1; Figs. 2 and 3).Fig. 2Results of RNA-seq analysis in SIM-treated group versus Control. (a) Bar graph representing the number of up/downregulated transcripts; with red: upregulated genes, blue: downregulated transcripts. The representation was done in Excel. (b) Venn diagram of upregulated transcripts in SIM-treated cells (blue) with FR > 1.5 or in the control group (yellow) with FR < -1.5. The overlapping area presents the number of genes that had -1.5 < FR < 1.5. The representation was done in Venny 2.1. (c) Vulcano plot of all genes; with red: upregulated genes, blue: downregulated genes. R was used for this representation. (d) Bar plot showing the enriched Gene Ontology (GO) terms for activated (left, upregulated) and suppressed (right, downregulated) processes grouped by three colored categories: blue for Biological Process (BP), red for Cellular Component (CC), and green for Molecular Function (MF); R was used for this representation. (e) Dot plot of enriched KEGG pathways—suppressed (left side) and activated (right side) pathways; R was used for this representation. (f) Supervised hierarchical clustering analysis of selected DEG in the control versus SIM-treated group in B16.F10 melanoma cells under normoxic conditions. Heatmap Clustering of 31 genes was generated using normalized FPKM values. Each column represents a biological replicate/group (CTR_R1, CTR_R2, CTR_R3 replicates of the gene expression in untreated cells and SIM_R1, SIM_R2, SIM_R3 replicates of the gene expression in SIM-treated cells), and each row represents a specific transcript. The level of each gene’s expression in a single sample is displayed in accordance with the color scale, red color represents relative increase in transcript abundance (positive Z-scores; 0 < Z-score ≤ 1.5), blue color represents relative decrease (negative Z-scores; -1.5 ≤ Z-score < 0), while white indicates median gene expression (Z-score close to zero). Names of the corresponding metabolic pathway for each gene were listed on the right of the heatmap. Genes with FR ≥ ± 1.5, p < 0.05, FDR 20% were considered differentially expressed.Table 1DEGs in metabolism.Transcript_IDGene_IDFRp-valueFDRPathwayGene_nameGene_descriptionENSMUST00000017534ENSMUSG000000173902.060.0030.064GlycolysisALDOCaldolase C, fructose-bisphosphate [Source:MGI Symbol;Acc:MGI:101863]ENSMUST00000125436ENSMUSG000000042671.970.0250.177GlycolysisENO2enolase 2, gamma neuronal [Source:MGI Symbol;Acc:MGI:95394]ENSMUST00000045702ENSMUSG000000360672.570.0110.117GlycolysisSLC2A6solute carrier family 2 (facilitated glucose transporter), member 6 [Source:MGI Symbol;Acc:MGI:2443286]ENSMUST00000143441ENSMUSG000000318071.870.0300.197PPPPGLS6-phosphogluconolactonase [Source:MGI Symbol;Acc:MGI:1913421]ENSMUST00000004327ENSMUSG000000314001.500.0000.038PPPG6PDglucose-6-phosphate dehydrogenase [Source:MGI Symbol;Acc:MGI:105979]ENSMUST00000097709ENSMUSG000000259501.720.0070.095TCA cycleIDH1isocitrate dehydrogenase 1 (NADP+), soluble [Source:MGI Symbol;Acc:MGI:96413]ENSMUST00000003622ENSMUSG000000035281.960.0010.047TCA cycleSLC25A1solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1 [Source:MGI Symbol;Acc:MGI:1345283]ENSMUST00000165111ENSMUSG000000209171.650.0040.075TCA cycleACLYATP citrate lyase [Source:MGI Symbol;Acc:MGI:103251]ENSMUST00000088452ENSMUSG000000231691.500.0260.182Glutamine metabolismSLC38A1solute carrier family 38, member 1 [Source:MGI Symbol;Acc:MGI:2145895]ENSMUST00000023099ENSMUSG000000224621.640.0070.096Glutamine metabolismSLC38A2solute carrier family 38, member 2 [Source:MGI Symbol;Acc:MGI:1915010]ENSMUST00000004634ENSMUSG000000201421.550.0040.077Glutamine metabolismSLC1A4solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 [Source:MGI Symbol;Acc:MGI:2135601]ENSMUST00000033283ENSMUSG00000030978-1.740.0060.091Glutamine metabolismRRM1ribonucleotide reductase M1 [Source:MGI Symbol;Acc:MGI:98180]ENSMUST00000147789ENSMUSG00000020649-2.230.0120.121Glutamine metabolismRRM2ribonucleotide reductase M2 [Source:MGI Symbol;Acc:MGI:98181]ENSMUST00000001715ENSMUSG000000016651.540.0140.134Glutamine metabolismGSTT3glutathione S-transferase, theta 3 [Source:MGI Symbol;Acc:MGI:2143526]ENSMUST00000049004ENSMUSG000000390624.700.0210.165Glutamine metabolismANPEPalanyl (membrane) aminopeptidase [Source:MGI Symbol;Acc:MGI:5000466]ENSMUST00000113658ENSMUSG000000299921.500.0040.077Glutamine metabolismGFPT1glutamine fructose-6-phosphate transaminase 1 [Source:MGI Symbol;Acc:MGI:95698]ENSMUST00000082392ENSMUSG000000643411.730.0100.114OXPHOSmt-ND1mitochondrially encoded NADH dehydrogenase 1 [Source:MGI Symbol;Acc:MGI:101787]ENSMUST00000082396ENSMUSG000000643451.680.0050.083OXPHOSmt-ND2mitochondrially encoded NADH dehydrogenase 2 [Source:MGI Symbol;Acc:MGI:102500]ENSMUST00000082414ENSMUSG000000643631.960.0030.064OXPHOSmt-ND4mitochondrially encoded NADH dehydrogenase 4 [Source:MGI Symbol;Acc:MGI:102498]ENSMUST00000084013ENSMUSG000000659472.120.0070.095OXPHOSmt-ND4Lmitochondrially encoded NADH dehydrogenase 4L [Source:MGI Symbol;Acc:MGI:102497]ENSMUST00000144285ENSMUSG00000040048-1.530.0290.193OXPHOSNdufb10NADH:ubiquinone oxidoreductase subunit B10 [Source:MGI Symbol;Acc:MGI:1915592]ENSMUST00000082421ENSMUSG000000643702.050.0060.089OXPHOSmt-CYTBmitochondrially encoded cytochrome b [Source:MGI Symbol;Acc:MGI:102501]ENSMUST00000207851ENSMUSG000000367514.000.0340.196OXPHOSCOX6B1cytochrome c oxidase, subunit 6B1 [Source:MGI Symbol;Acc:MGI:107460]ENSMUST00000082405ENSMUSG000000643541.780.0260.182OXPHOSmt-CO2mitochondrially encoded cytochrome c oxidase II [Source:MGI Symbol;Acc:MGI:102503]ENSMUST00000082407ENSMUSG000000643561.550.0220.168OXPHOSmt-ATP8mitochondrially encoded ATP synthase 8 [Source:MGI Symbol;Acc:MGI:99926]ENSMUST00000132866ENSMUSG00000058440-1.860.0080.104OXPHOSNRF1nuclear respiratory factor 1 [Source:MGI Symbol;Acc:MGI:1332235]ENSMUST00000089449ENSMUSG000000331749.180.002 0.062 LipolysisMAGLMonoacylglycerol lipase (monoglyceride lipase) [Source:MGI Symbol;Acc:MGI:1346042]ENSMUST00000164016ENSMUSG000000255091.92 0.002 0.061 LipolysisATGLadipose triglyceride lipase (patatin-like phospholipase domain containing 2) [Source:MGI Symbol;Acc:MGI:1914103]ENSMUST00000123539ENSMUSG000000276955.280.017 0.148 LipolysisPLD1phospholipase D1 [Source:MGI Symbol;Acc:MGI:109585]ENSMUST00000055655ENSMUSG000000251531.990.0020.055FASFASNfatty acid synthase [Source:MGI Symbol;Acc:MGI:95485]ENSMUST00000071402ENSMUSG000000412202.020.0040.076FASELOVL6ELOVL family member 6, elongation of long chain fatty acids (yeast) [Source:MGI Symbol;Acc:MGI:2156528]ENSMUST00000022207ENSMUSG000000216962.400.0030.068FASELOVL7ELOVL family member 7, elongation of long chain fatty acids (yeast) [Source:MGI Symbol;Acc:MGI:1921809]ENSMUST00000061156ENSMUSG000000353761.520.0210.165FASHACD23-hydroxyacyl-CoA dehydratase 2 [Source:MGI Symbol;Acc:MGI:1918007]ENSMUST00000080065ENSMUSG000000593161.660.0000.019FASSLC27A4solute carrier family 27 (fatty acid transporter), member 4 [Source:MGI Symbol;Acc:MGI:1347347]ENSMUST00000041331ENSMUSG000000370711.860.005 0.083 FASSCD1stearoyl-Coenzyme A desaturase 1 [Source:MGI Symbol;Acc:MGI:98239]ENSMUST00000029135ENSMUSG000000276051.870.0000.022FAOACSS2acyl-CoA synthetase short-chain family member 2 [Source:MGI Symbol;Acc:MGI:1890410]ENSMUST00000068947ENSMUSG000000290982.130.0060.093FAOACOX3acyl-Coenzyme A oxidase 3, pristanoyl, peroxisomal [Source:MGI Symbol;Acc:MGI:1933156]ENSMUST00000144016ENSMUSG000000150902.81 0.001 0.042 Prostaglandin metabolismPGDSprostaglandin D2 synthase (brain) [Source:MGI Symbol;Acc:MGI:99261]15-prostaglandin dehydrogenase (1.15-PGDH), acetyl-Coenzyme A acetyl-transferase 2 (ACAT2), acyl-Coenzyme A oxidase 3 (ACOX3), protein kinase B (also known as serine/threonine-specific protein kinases) (Akt), aldolase C (ALDOC), adenosine monophosphate (AMP), alanyl aminopeptidase (ANPEP), adenosine diphosphate (ADP), adipose triglyceride lipase (ATGL), ATP citrate lyase (ACLY), citrate synthase (CS), differentially expressed genes (DEGs), 5,5’-Dithiobis-2-Nitrobenzoic Acid (DTNB), eukaryotic translation initiation factor 4A1 (eIF4A1), enolase 2 (Eno2), endoplasmic reticulum (ER), electron transport chain (ETC), elongation of long chain fatty acids family (ELOVL), fatty acids elongation (FAE), β-oxidation (FAO), farnesyl diphosphate synthase (FDPS), forkhead box M1 (FOXM1), glucose 6-Phosphate Dehydrogenase (G6PD), glutamine fructose-6-phosphate transaminase 1 (GFPT1), glucose transporter 1 (GLUT1), L-γ-glutamyl-p-nitroanilide (GPNA), glutathione S-transferase theta 3 (GST theta 3), 3-hydroxy-acyl-CoA dehydrogenase (HACD2), hydroxy-3-methylglutaryl-Coenzyme A reductase (HMG-CR), 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (HMG-CS1), heat shock protein 90 (HSP90), isopentenyl-diphosphate isomerase (IDI1), isocitrate dehydrogenase 1 (IDH1), insulin-induced gene protein 1 (INSIG-1), insulin-induced gene protein 2 (INSIG-2), Lactate Dehydrogenase (LDH), monoacylglycerol lipase (MAGL), mitochondrially encoded NADH dehydrogenase 1 (mt-ND1), mevalonate (diphospho) decarboxylase (MVD), NADH Oxidoreductase Subunit B10 (Ndufb10), nuclear respiratory factor 1 (NRF1), oxidative phosphorylation (OXPHOS), pyruvate dehydrogenase (PDH), PDH kinase-1 (PDK-1), phosphofructokinase 1 (PFK1), 6-phosphogluconolactonase (PGLS), PTEN induced putative kinase 1 (PINK1), prostaglandin D2 synthase (PGDS), protein kinase B (PKB), phospholipase D1 (PLD1), pentose phosphate pathway (PPP), ribosomal protein S6 (RPS6), ribosomal protein S6 kinase polypeptide 2 (Rps6kb2), ribonucleotide reductase 1 (RRM1), ribonucleotide reductase 2 (RRM2), simvastatin (SIM), stearyl Co-A desaturase 1 (SCD1), saturated fatty acids (SFA), solute carrier family 1 glutamate transporter, member 4 (SLC1A4), solute carrier family 2, member 1 (GLUT1) (SLC2A1), solute carrier family 25 member 1 (SLC25A1), solute carrier transporter member 4 (SLC27A4), solute carrier family 38, member 1 (SLC38A1), squalene epoxidase (SQLE), sterol regulatory element binding proteins (SREBP1), tricarboxylic acid cycle (TCA), unsaturated fatty acids (UFAs).Fig. 3Integrated schematic overview of the effects of SIM on the expression of genes encoding for proteins involved in metabolic pathways in B16.F10 murine melanoma cells, with complementary protein levels and catalytic activities results. Red outlines indicate the up-regulated genes and green outlines indicate the down-regulated genes which were revealed by RNA-Seq analysis. Created in BioRender. Gabriela, G. (2024) BioRender.com/h93z324. Permission has been obtained from Kanehisa Laboratories for using KEGG pathway database, which served as source for all reaction stages49–51. Results of RNA-seq analysis in SIM-treated group versus Control. (a) Bar graph representing the number of up/downregulated transcripts; with red: upregulated genes, blue: downregulated transcripts. The representation was done in Excel. (b) Venn diagram of upregulated transcripts in SIM-treated cells (blue) with FR > 1.5 or in the control group (yellow) with FR < -1.5. The overlapping area presents the number of genes that had -1.5 < FR < 1.5. The representation was done in Venny 2.1. (c) Vulcano plot of all genes; with red: upregulated genes, blue: downregulated genes. R was used for this representation. (d) Bar plot showing the enriched Gene Ontology (GO) terms for activated (left, upregulated) and suppressed (right, downregulated) processes grouped by three colored categories: blue for Biological Process (BP), red for Cellular Component (CC), and green for Molecular Function (MF); R was used for this representation. (e) Dot plot of enriched KEGG pathways—suppressed (left side) and activated (right side) pathways; R was used for this representation. (f) Supervised hierarchical clustering analysis of selected DEG in the control versus SIM-treated group in B16.F10 melanoma cells under normoxic conditions. Heatmap Clustering of 31 genes was generated using normalized FPKM values. Each column represents a biological replicate/group (CTR_R1, CTR_R2, CTR_R3 replicates of the gene expression in untreated cells and SIM_R1, SIM_R2, SIM_R3 replicates of the gene expression in SIM-treated cells), and each row represents a specific transcript. The level of each gene’s expression in a single sample is displayed in accordance with the color scale, red color represents relative increase in transcript abundance (positive Z-scores; 0 < Z-score ≤ 1.5), blue color represents relative decrease (negative Z-scores; -1.5 ≤ Z-score < 0), while white indicates median gene expression (Z-score close to zero). Names of the corresponding metabolic pathway for each gene were listed on the right of the heatmap. Genes with FR ≥ ± 1.5, p < 0.05, FDR 20% were considered differentially expressed. Table 1DEGs in metabolism.Transcript_IDGene_IDFRp-valueFDRPathwayGene_nameGene_descriptionENSMUST00000017534ENSMUSG000000173902.060.0030.064GlycolysisALDOCaldolase C, fructose-bisphosphate [Source:MGI Symbol;Acc:MGI:101863]ENSMUST00000125436ENSMUSG000000042671.970.0250.177GlycolysisENO2enolase 2, gamma neuronal [Source:MGI Symbol;Acc:MGI:95394]ENSMUST00000045702ENSMUSG000000360672.570.0110.117GlycolysisSLC2A6solute carrier family 2 (facilitated glucose transporter), member 6 [Source:MGI Symbol;Acc:MGI:2443286]ENSMUST00000143441ENSMUSG000000318071.870.0300.197PPPPGLS6-phosphogluconolactonase [Source:MGI Symbol;Acc:MGI:1913421]ENSMUST00000004327ENSMUSG000000314001.500.0000.038PPPG6PDglucose-6-phosphate dehydrogenase [Source:MGI Symbol;Acc:MGI:105979]ENSMUST00000097709ENSMUSG000000259501.720.0070.095TCA cycleIDH1isocitrate dehydrogenase 1 (NADP+), soluble [Source:MGI Symbol;Acc:MGI:96413]ENSMUST00000003622ENSMUSG000000035281.960.0010.047TCA cycleSLC25A1solute carrier family 25 (mitochondrial carrier, citrate transporter), member 1 [Source:MGI Symbol;Acc:MGI:1345283]ENSMUST00000165111ENSMUSG000000209171.650.0040.075TCA cycleACLYATP citrate lyase [Source:MGI Symbol;Acc:MGI:103251]ENSMUST00000088452ENSMUSG000000231691.500.0260.182Glutamine metabolismSLC38A1solute carrier family 38, member 1 [Source:MGI Symbol;Acc:MGI:2145895]ENSMUST00000023099ENSMUSG000000224621.640.0070.096Glutamine metabolismSLC38A2solute carrier family 38, member 2 [Source:MGI Symbol;Acc:MGI:1915010]ENSMUST00000004634ENSMUSG000000201421.550.0040.077Glutamine metabolismSLC1A4solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 [Source:MGI Symbol;Acc:MGI:2135601]ENSMUST00000033283ENSMUSG00000030978-1.740.0060.091Glutamine metabolismRRM1ribonucleotide reductase M1 [Source:MGI Symbol;Acc:MGI:98180]ENSMUST00000147789ENSMUSG00000020649-2.230.0120.121Glutamine metabolismRRM2ribonucleotide reductase M2 [Source:MGI Symbol;Acc:MGI:98181]ENSMUST00000001715ENSMUSG000000016651.540.0140.134Glutamine metabolismGSTT3glutathione S-transferase, theta 3 [Source:MGI Symbol;Acc:MGI:2143526]ENSMUST00000049004ENSMUSG000000390624.700.0210.165Glutamine metabolismANPEPalanyl (membrane) aminopeptidase [Source:MGI Symbol;Acc:MGI:5000466]ENSMUST00000113658ENSMUSG000000299921.500.0040.077Glutamine metabolismGFPT1glutamine fructose-6-phosphate transaminase 1 [Source:MGI Symbol;Acc:MGI:95698]ENSMUST00000082392ENSMUSG000000643411.730.0100.114OXPHOSmt-ND1mitochondrially encoded NADH dehydrogenase 1 [Source:MGI Symbol;Acc:MGI:101787]ENSMUST00000082396ENSMUSG000000643451.680.0050.083OXPHOSmt-ND2mitochondrially encoded NADH dehydrogenase 2 [Source:MGI Symbol;Acc:MGI:102500]ENSMUST00000082414ENSMUSG000000643631.960.0030.064OXPHOSmt-ND4mitochondrially encoded NADH dehydrogenase 4 [Source:MGI Symbol;Acc:MGI:102498]ENSMUST00000084013ENSMUSG000000659472.120.0070.095OXPHOSmt-ND4Lmitochondrially encoded NADH dehydrogenase 4L [Source:MGI Symbol;Acc:MGI:102497]ENSMUST00000144285ENSMUSG00000040048-1.530.0290.193OXPHOSNdufb10NADH:ubiquinone oxidoreductase subunit B10 [Source:MGI Symbol;Acc:MGI:1915592]ENSMUST00000082421ENSMUSG000000643702.050.0060.089OXPHOSmt-CYTBmitochondrially encoded cytochrome b [Source:MGI Symbol;Acc:MGI:102501]ENSMUST00000207851ENSMUSG000000367514.000.0340.196OXPHOSCOX6B1cytochrome c oxidase, subunit 6B1 [Source:MGI Symbol;Acc:MGI:107460]ENSMUST00000082405ENSMUSG000000643541.780.0260.182OXPHOSmt-CO2mitochondrially encoded cytochrome c oxidase II [Source:MGI Symbol;Acc:MGI:102503]ENSMUST00000082407ENSMUSG000000643561.550.0220.168OXPHOSmt-ATP8mitochondrially encoded ATP synthase 8 [Source:MGI Symbol;Acc:MGI:99926]ENSMUST00000132866ENSMUSG00000058440-1.860.0080.104OXPHOSNRF1nuclear respiratory factor 1 [Source:MGI Symbol;Acc:MGI:1332235]ENSMUST00000089449ENSMUSG000000331749.180.002 0.062 LipolysisMAGLMonoacylglycerol lipase (monoglyceride lipase) [Source:MGI Symbol;Acc:MGI:1346042]ENSMUST00000164016ENSMUSG000000255091.92 0.002 0.061 LipolysisATGLadipose triglyceride lipase (patatin-like phospholipase domain containing 2) [Source:MGI Symbol;Acc:MGI:1914103]ENSMUST00000123539ENSMUSG000000276955.280.017 0.148 LipolysisPLD1phospholipase D1 [Source:MGI Symbol;Acc:MGI:109585]ENSMUST00000055655ENSMUSG000000251531.990.0020.055FASFASNfatty acid synthase [Source:MGI Symbol;Acc:MGI:95485]ENSMUST00000071402ENSMUSG000000412202.020.0040.076FASELOVL6ELOVL family member 6, elongation of long chain fatty acids (yeast) [Source:MGI Symbol;Acc:MGI:2156528]ENSMUST00000022207ENSMUSG000000216962.400.0030.068FASELOVL7ELOVL family member 7, elongation of long chain fatty acids (yeast) [Source:MGI Symbol;Acc:MGI:1921809]ENSMUST00000061156ENSMUSG000000353761.520.0210.165FASHACD23-hydroxyacyl-CoA dehydratase 2 [Source:MGI Symbol;Acc:MGI:1918007]ENSMUST00000080065ENSMUSG000000593161.660.0000.019FASSLC27A4solute carrier family 27 (fatty acid transporter), member 4 [Source:MGI Symbol;Acc:MGI:1347347]ENSMUST00000041331ENSMUSG000000370711.860.005 0.083 FASSCD1stearoyl-Coenzyme A desaturase 1 [Source:MGI Symbol;Acc:MGI:98239]ENSMUST00000029135ENSMUSG000000276051.870.0000.022FAOACSS2acyl-CoA synthetase short-chain family member 2 [Source:MGI Symbol;Acc:MGI:1890410]ENSMUST00000068947ENSMUSG000000290982.130.0060.093FAOACOX3acyl-Coenzyme A oxidase 3, pristanoyl, peroxisomal [Source:MGI Symbol;Acc:MGI:1933156]ENSMUST00000144016ENSMUSG000000150902.81 0.001 0.042 Prostaglandin metabolismPGDSprostaglandin D2 synthase (brain) [Source:MGI Symbol;Acc:MGI:99261]15-prostaglandin dehydrogenase (1.15-PGDH), acetyl-Coenzyme A acetyl-transferase 2 (ACAT2), acyl-Coenzyme A oxidase 3 (ACOX3), protein kinase B (also known as serine/threonine-specific protein kinases) (Akt), aldolase C (ALDOC), adenosine monophosphate (AMP), alanyl aminopeptidase (ANPEP), adenosine diphosphate (ADP), adipose triglyceride lipase (ATGL), ATP citrate lyase (ACLY), citrate synthase (CS), differentially expressed genes (DEGs), 5,5’-Dithiobis-2-Nitrobenzoic Acid (DTNB), eukaryotic translation initiation factor 4A1 (eIF4A1), enolase 2 (Eno2), endoplasmic reticulum (ER), electron transport chain (ETC), elongation of long chain fatty acids family (ELOVL), fatty acids elongation (FAE), β-oxidation (FAO), farnesyl diphosphate synthase (FDPS), forkhead box M1 (FOXM1), glucose 6-Phosphate Dehydrogenase (G6PD), glutamine fructose-6-phosphate transaminase 1 (GFPT1), glucose transporter 1 (GLUT1), L-γ-glutamyl-p-nitroanilide (GPNA), glutathione S-transferase theta 3 (GST theta 3), 3-hydroxy-acyl-CoA dehydrogenase (HACD2), hydroxy-3-methylglutaryl-Coenzyme A reductase (HMG-CR), 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (HMG-CS1), heat shock protein 90 (HSP90), isopentenyl-diphosphate isomerase (IDI1), isocitrate dehydrogenase 1 (IDH1), insulin-induced gene protein 1 (INSIG-1), insulin-induced gene protein 2 (INSIG-2), Lactate Dehydrogenase (LDH), monoacylglycerol lipase (MAGL), mitochondrially encoded NADH dehydrogenase 1 (mt-ND1), mevalonate (diphospho) decarboxylase (MVD), NADH Oxidoreductase Subunit B10 (Ndufb10), nuclear respiratory factor 1 (NRF1), oxidative phosphorylation (OXPHOS), pyruvate dehydrogenase (PDH), PDH kinase-1 (PDK-1), phosphofructokinase 1 (PFK1), 6-phosphogluconolactonase (PGLS), PTEN induced putative kinase 1 (PINK1), prostaglandin D2 synthase (PGDS), protein kinase B (PKB), phospholipase D1 (PLD1), pentose phosphate pathway (PPP), ribosomal protein S6 (RPS6), ribosomal protein S6 kinase polypeptide 2 (Rps6kb2), ribonucleotide reductase 1 (RRM1), ribonucleotide reductase 2 (RRM2), simvastatin (SIM), stearyl Co-A desaturase 1 (SCD1), saturated fatty acids (SFA), solute carrier family 1 glutamate transporter, member 4 (SLC1A4), solute carrier family 2, member 1 (GLUT1) (SLC2A1), solute carrier family 25 member 1 (SLC25A1), solute carrier transporter member 4 (SLC27A4), solute carrier family 38, member 1 (SLC38A1), squalene epoxidase (SQLE), sterol regulatory element binding proteins (SREBP1), tricarboxylic acid cycle (TCA), unsaturated fatty acids (UFAs). DEGs in metabolism. 15-prostaglandin dehydrogenase (1.15-PGDH), acetyl-Coenzyme A acetyl-transferase 2 (ACAT2), acyl-Coenzyme A oxidase 3 (ACOX3), protein kinase B (also known as serine/threonine-specific protein kinases) (Akt), aldolase C (ALDOC), adenosine monophosphate (AMP), alanyl aminopeptidase (ANPEP), adenosine diphosphate (ADP), adipose triglyceride lipase (ATGL), ATP citrate lyase (ACLY), citrate synthase (CS), differentially expressed genes (DEGs), 5,5’-Dithiobis-2-Nitrobenzoic Acid (DTNB), eukaryotic translation initiation factor 4A1 (eIF4A1), enolase 2 (Eno2), endoplasmic reticulum (ER), electron transport chain (ETC), elongation of long chain fatty acids family (ELOVL), fatty acids elongation (FAE), β-oxidation (FAO), farnesyl diphosphate synthase (FDPS), forkhead box M1 (FOXM1), glucose 6-Phosphate Dehydrogenase (G6PD), glutamine fructose-6-phosphate transaminase 1 (GFPT1), glucose transporter 1 (GLUT1), L-γ-glutamyl-p-nitroanilide (GPNA), glutathione S-transferase theta 3 (GST theta 3), 3-hydroxy-acyl-CoA dehydrogenase (HACD2), hydroxy-3-methylglutaryl-Coenzyme A reductase (HMG-CR), 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 1 (HMG-CS1), heat shock protein 90 (HSP90), isopentenyl-diphosphate isomerase (IDI1), isocitrate dehydrogenase 1 (IDH1), insulin-induced gene protein 1 (INSIG-1), insulin-induced gene protein 2 (INSIG-2), Lactate Dehydrogenase (LDH), monoacylglycerol lipase (MAGL), mitochondrially encoded NADH dehydrogenase 1 (mt-ND1), mevalonate (diphospho) decarboxylase (MVD), NADH Oxidoreductase Subunit B10 (Ndufb10), nuclear respiratory factor 1 (NRF1), oxidative phosphorylation (OXPHOS), pyruvate dehydrogenase (PDH), PDH kinase-1 (PDK-1), phosphofructokinase 1 (PFK1), 6-phosphogluconolactonase (PGLS), PTEN induced putative kinase 1 (PINK1), prostaglandin D2 synthase (PGDS), protein kinase B (PKB), phospholipase D1 (PLD1), pentose phosphate pathway (PPP), ribosomal protein S6 (RPS6), ribosomal protein S6 kinase polypeptide 2 (Rps6kb2), ribonucleotide reductase 1 (RRM1), ribonucleotide reductase 2 (RRM2), simvastatin (SIM), stearyl Co-A desaturase 1 (SCD1), saturated fatty acids (SFA), solute carrier family 1 glutamate transporter, member 4 (SLC1A4), solute carrier family 2, member 1 (GLUT1) (SLC2A1), solute carrier family 25 member 1 (SLC25A1), solute carrier transporter member 4 (SLC27A4), solute carrier family 38, member 1 (SLC38A1), squalene epoxidase (SQLE), sterol regulatory element binding proteins (SREBP1), tricarboxylic acid cycle (TCA), unsaturated fatty acids (UFAs). Integrated schematic overview of the effects of SIM on the expression of genes encoding for proteins involved in metabolic pathways in B16.F10 murine melanoma cells, with complementary protein levels and catalytic activities results. Red outlines indicate the up-regulated genes and green outlines indicate the down-regulated genes which were revealed by RNA-Seq analysis. Created in BioRender. Gabriela, G. (2024) BioRender.com/h93z324. Permission has been obtained from Kanehisa Laboratories for using KEGG pathway database, which served as source for all reaction stages49–51. These findings, linked with the upregulation of mRNA level for prostaglandin D2 synthase (PGDS) (FR = 2.81; p = 0.001), might be consistent with a SIM-induced increase in prostaglandin synthesis in melanoma cells (Table 1; Figs. 2 and 3). Moreover, multiple aggressiveness-associated markers were notably upregulated in SIM-treated cells, including mRNA expression of signal transducer and activator of transcription 3 (STAT3, FR = 1.75, p < 0.01), activating transcription factor 3 (ATF3, FR = 2.38, p < 0.05), forkhead box R2 (Foxr2, FR = 1.71, p < 0.01), angiopoietin-like 2 (Angptl2, FR = 2.4, p < 0.01), erb-b2 receptor tyrosine kinase 3 (Her3/Erbb3, FR = 3.38, p < 0.001), AHNAK nucleoprotein 2 (Ahnak2, FR = 4.51, p < 0.05) and Ezrin (Ezr, FR = 1.63, p < 0.05), among a total of 45 upregulated transcripts associated with an aggressive phenotype, compared to control group (Supplementary Table 4—deposited in GEO under accession GSE329678)52–64. Finally, our transcriptomics findings indicated that excepting for glutamine related ribonucleotide synthesis, SIM enhanced glutamine utilization, implied by increased expression of glutamine transporters or enzymes such as SLC1A4 (FR = 1.55; p = 0.0041), alanyl aminopeptidase (ANPEP) (FR = 4.69; p = 0.0214) and glutamine fructose-6-phosphate transaminase 1 (GFPT1) (FR = 1.5; p = 0.0043) (Table 1; Figs. 2 and 3). Because glutamine metabolism can replenish TCA cycle intermediates, it provides a carbon and nitrogen source for energy, nucleotide and lipid synthesis, promoting cell proliferation65–70. Altogether, our RNA-seq data suggested that SIM treatment enhanced cell metabolism at mRNA level in B16.F10 melanoma cells compared to control cells, mainly by upregulating mRNA expression of genes encoding for: transporters of glucose, glutamine and FAs, glucose metabolism, mitochondrial oxidative metabolism and lipid metabolism. Investigation of the SIM effects on the metabolism of B16.F10 melanoma cells at protein level To assess whether transcriptomics changes induced by SIM administration might be seen at the protein level, we evaluated selected proteins with a key role in cancer cell metabolism for their catalytic activity, through enzymatic assays (Fig. 4) and protein production (Fig. 5) by western blot analysis. To investigate whether SIM treatment influenced glucose metabolism, we determined whether the uptake of glucose through one isoform of the family of facilitated glucose transporters, GLUT1 was affected by treatment. While SIM did not affect GLUT1 mRNA expression (p > 0.05) (Supplementary Table 1—repository), GLUT1 protein levels were increased approximately twofold following SIM treatment (Fig. 5 a, b), suggesting a potential alteration in glucose transport capacity. Notably, only two glycolytic genes, namely AldoC and Eno2, were upregulated by SIM (Table 1). Although our transcriptomic data showed no significant changes in the mRNA expression of key glycolytic enzymes such as PFK1 and LDH (Supplementary Table 1—repository), their catalytic activities were significantly reduced in the SIM-treated group compared to control. PFK1 activity decreased by almost 30% (p < 0.0001; Fig. 4 a), and LDH activity was reduced by 25% (Fig. 4 b), indirectly suggesting reduced lactate production in SIM-treated group. Similarly, despite increased mRNA levels of PPP- related genes, the catalytic activity of G6PD, the rate-limiting enzyme of the PPP, was decreased 30% (p < 0.01) (Fig. 4 c) suggesting an overall reduced pathway activity. This alteration likely led to a decrease in the NADPH synthesis, which may affectboth redox homeostasis and nucleotide synthesis in which PPP intermediates take part in. Despite transcriptomics information revealing no changes in mRNA expression of genes in TCA cycle, except IDH1 (Supplementary Table 1—repository), there was a significant threefold increase (p < 0.0001) in the catalytic activity of CS (Fig. 4 d), the first rate-limiting enzyme of TCA, which may suggest a mild re-triggering of TCA cycle activity in melanoma cells following SIM administration compared to the control. Although our transcriptomics data suggested increased mRNA expression of genes involved in OXPHOS and peroxisomal FAO, the protein expression of mt-ND1 was slightly reduced in SIM-treated cells compared to control (Table 1; Fig. 5 a,c). Using transcriptomics data, we found that at mRNA level, both saturated FAS main enzyme FASN, and SCD1 the enzyme responsible for converting saturated FAs (SFAs) to UFAs exhibited significant increase in expression in SIM group compared to the control (Table 1). The expression signature was also seen at the protein level, with a significant twofold increase for FASN (Table 1; Fig. 5 a,d), and threefold increase for SCD1 (Fig. 5 a,e) compared to control. The ACOX3 protein expression, enzyme crucial for peroxisomal FAO, was similar in SIM treated cells compared to the control (Table 1; Fig. 5 a,f). The observed increase in lipid metabolism and the preference for UFAs production in SIM-treated cells suggested an expected rise in the availability of MUFAs, providing protective effects against lipid peroxidation and endoplasmic reticulum (ER) stress71–73, and of PUFAs, that most likely led to 20% increase in the level of prostaglandins (PGD2) in SIM-treated cells compared to control (Supplementary Fig. 4 a) which could have significant implications for cellular processes20,23. Moreover, the interaction network of the proteins encoded by the DEGs involved in the selected metabolic pathways indicated that these genes were grouped in 10 different clusters (Fig. 6; Supplementary Table 3—deposited in GEO under accession GSE329678). Thus, the top ten genes with the most connections included genes for FASN of FAS process and MVD and other eight mevalonate/cholesterol biosynthesis genes, with Lanosterol synthase (LSS) gene possessing the highest node degree of 14 (Supplementary Table 3—repository). Given the roles of STAT3 and c-JUN in melanoma progression and their transcriptional upregulation following SIM treatment (Supplementary Table 1—repository), we assessed their protein expression by ELISA and detected no corresponding changes (in Sim-treated versus untreated cells), suggesting that SIM-driven metabolic reprogramming does not translate into increased protein expression of these factors in melanoma cells (Supplementary Fig. 4).Fig. 4Effects of SIM on the catalytic activities of specific enzymes in B16.F10 melanoma cells. Graphical representations of catalytic activities of different enzymes in lysates of B16.F10 cells treated with 3.5 μM SIM for 24 h in normoxia compared to control: (a) PFK activity expressed as mU/ml; (b) LDH activity expressed as mU/mg protein; (c) G6PD activity expressed as mU/ml; (d) CS activity represented as mU/ml. All data were expressed mean ± SD of at least three independent experiments. T-test was used for statistical analysis of the data; *, p < 0.05; **, p < 0.01; ****, p < 0.0001.Fig. 5Western blot analysis of the effects of SIM on specific protein levels in B16.F10 melanoma cells. Western blot images (a) and their corresponding graphs showing the percentage of protein levels after administration of 3.5 μM SIM for 24 h, in normoxia, as compared to control levels of the same proteins; (b) GLUT1 protein expression; (c) mt-ND1 protein expression; (d) FASN protein expression; (e) SCD1 protein expression; (f) ACOX3 and β-actin was used as loading control. All data were expressed mean ± SD of at least three independent experiments. T-test was used for statistical analysis of the data; *, p < 0.05; **, p < 0.01; ns: not significant. Original blots are presented in Supplementary Figs. 10–14.Fig. 6PPI network of DEGs involved in selected metabolic pathways. STRING (version 12.0, https://string-db.org/) was used for this representation, with 0.7 confidence score, clustered using Markov Cluster Algorithm (MCL); each cluster is represented with a different color: Red: 1, Sterol biosynthesis; Brown: 2, Oxidative phosphorylation; Dark Goldenrod: 3, Fatty acid degradation; Green Yellow: 4, Citrate cycle (TCA cycle); Cyan: 5, Pentose phosphate pathway; Green: 6, Fatty acyl-CoA biosynthesis; Blue: 7, Regulation of lipolysis in adipocytes; Light Sky Blue: 8, Glycosphingolipid metabolism; Medium Blue: 9, Glycerophospholipid metabolism; Purple: 10, Synthesis of UDP-N-acetyl-glucosamine/Nucleotide-sugar biosynthesis. Effects of SIM on the catalytic activities of specific enzymes in B16.F10 melanoma cells. Graphical representations of catalytic activities of different enzymes in lysates of B16.F10 cells treated with 3.5 μM SIM for 24 h in normoxia compared to control: (a) PFK activity expressed as mU/ml; (b) LDH activity expressed as mU/mg protein; (c) G6PD activity expressed as mU/ml; (d) CS activity represented as mU/ml. All data were expressed mean ± SD of at least three independent experiments. T-test was used for statistical analysis of the data; *, p < 0.05; **, p < 0.01; ****, p < 0.0001. Western blot analysis of the effects of SIM on specific protein levels in B16.F10 melanoma cells. Western blot images (a) and their corresponding graphs showing the percentage of protein levels after administration of 3.5 μM SIM for 24 h, in normoxia, as compared to control levels of the same proteins; (b) GLUT1 protein expression; (c) mt-ND1 protein expression; (d) FASN protein expression; (e) SCD1 protein expression; (f) ACOX3 and β-actin was used as loading control. All data were expressed mean ± SD of at least three independent experiments. T-test was used for statistical analysis of the data; *, p < 0.05; **, p < 0.01; ns: not significant. Original blots are presented in Supplementary Figs. 10–14. PPI network of DEGs involved in selected metabolic pathways. STRING (version 12.0, https://string-db.org/) was used for this representation, with 0.7 confidence score, clustered using Markov Cluster Algorithm (MCL); each cluster is represented with a different color: Red: 1, Sterol biosynthesis; Brown: 2, Oxidative phosphorylation; Dark Goldenrod: 3, Fatty acid degradation; Green Yellow: 4, Citrate cycle (TCA cycle); Cyan: 5, Pentose phosphate pathway; Green: 6, Fatty acyl-CoA biosynthesis; Blue: 7, Regulation of lipolysis in adipocytes; Light Sky Blue: 8, Glycosphingolipid metabolism; Medium Blue: 9, Glycerophospholipid metabolism; Purple: 10, Synthesis of UDP-N-acetyl-glucosamine/Nucleotide-sugar biosynthesis. Investigation of SIM effects on migration and invasive capacity of murine melanoma cells To evaluate whether SIM affected cell migration, invasion- and metastasis-related markers were assessed using wound healing and gelatin zymography assays. Our results indicated that cells treated with SIM showed a 54% wound closure after 24 h compared to initial percentage of wound closure area at time 0 (Fig. 7 a,b), while the activities of MMP-2 and -9 were similar to their correspondents in control group (Fig. 7 c,d), suggesting that SIM did not perform particular effects on these characteristics linked with resistance.Fig. 7SIM effects on cell migration and invasive capacity in B16.F10 melanoma cells. (a) Representative images from the wound healing assay showing scratch closure in B16.F10 cells treated with 3.5 μM SIM from 0 and 24 h compared to control; (b) Graphical representation of wound closure percentage quantified from the images in (A); (c) Representative images of MMP-2 and MMP-9 activity profiles in SIM-treated cells, compared to activity of the same proteins in control group, assessed by gelatin zymography; (d) Percentage of clearance, represented as bar graphs, was obtained by normalizing the area of clearance of SIM-treated cells to its correspondent in control (untreated) cells. Data are presented as mean ± SD. Statistical analysis was performed using t-test; ns, not significant; ***, p < 0.001. Original gels are presented in Supplementary Fig. 17. SIM effects on cell migration and invasive capacity in B16.F10 melanoma cells. (a) Representative images from the wound healing assay showing scratch closure in B16.F10 cells treated with 3.5 μM SIM from 0 and 24 h compared to control; (b) Graphical representation of wound closure percentage quantified from the images in (A); (c) Representative images of MMP-2 and MMP-9 activity profiles in SIM-treated cells, compared to activity of the same proteins in control group, assessed by gelatin zymography; (d) Percentage of clearance, represented as bar graphs, was obtained by normalizing the area of clearance of SIM-treated cells to its correspondent in control (untreated) cells. Data are presented as mean ± SD. Statistical analysis was performed using t-test; ns, not significant; ***, p < 0.001. Original gels are presented in Supplementary Fig. 17. Cross-species validation of SIM-induced effects in human A375 melanoma cells through functional and in silico comparative analyses To examine whether the antiproliferative effects of SIM were consistent across melanoma models, we performed an additional proliferation assay in the A375 human melanoma cell line. Cells were treated under comparable experimental conditions using SIM concentrations between 1.2–239 μM3. The results showed a similar inhibitory trend in cell proliferation, indicating that the response to SIM in human A375 was comparable to that observed in our previous analyses in B16.F10 murine melanoma cells (Supplementary Fig. 5)3. To evaluate whether the transcriptional effects of SIM were conserved between mouse and human melanoma cells, we compared our B16.F10 RNA-seq data with human melanoma transcriptional signatures from the LINCS L1000 dataset (ID: CPC005_A375_24H:BRD-A81772229-001–01-6:10). The human A375 melanoma cell line treated with 10 µM SIM for 24 h was selected as the primary reference, as it represented the closest available condition in terms of cell type and treatment duration. Mouse genes were matched to their human orthologs, enabling direct cross-species comparison. Cross-species concordance was assessed by correlating mouse log2 fold changes with human LINCS moderated z-scores. Given the differences in measurement scales between RNA-seq fold changes and LINCS z-scores, Spearman rank correlation was applied to evaluate monotonic correlation between datasets. A significant positive correlation with Spearman rho = 0.552 (p-value = 4.89E-14) was observed between mouse and human transcriptional responses, indicating a conserved transcriptional response across the two species. This association was particularly pronounced among statistically significant mouse DEG (FDR < 0.05), supporting the robustness of the cross-species overlap (Supplementary Fig. 5 a). A total of 158 genes were identified as commonly regulated across the two models, comprising both upregulated and downregulated transcripts. To further examine the association between gene regulation direction in mouse and human melanoma cells, genes were classified based on the direction of regulation in each species. A significant directional concordance between mouse and human gene regulation was observed (Fisher’s exact test, OR = 8, 95% CI 5.87–19.98, p < 0.0001). Overall, 74.6% of genes showed regulation in the same direction across the two datasets (Supplementary Table 5). Visualization of the top 20 concordantly regulated genes across mouse and human melanoma cells further illustrated the biological consistency of the SIM response. The most strongly upregulated genes, including kruppel-like factor 2, 4 (KLF4, KLF2), galectin 4 (LGALS4), integrin Subunit Beta 3 (ITGB3), and Human Epidermal Growth Factor Receptor 3 (ERBB3), are involved in transcriptional regulation, stress response, and adaptive signaling74–76. In contrast, the most strongly downregulated genes, such as Cell Division Cycle 20 (CDC20), Cyclin B2 (CCNB2) minichromosomal maintenance complex component 4 (MCM4) and lamin B1 (LMNB1) are essential regulators of DNA replication and mitotic progression77–80. This pattern highlights a coordinated transcriptional shift characterized by activation of adaptive cellular processed and a tendency towards suppression of cell cycle (Supplementary Fig. 5 b). To further characterize the functional context, we mapped significantly regulated genes with a |z|≥ 1 to pathway categories and assessed pathway association using DAVID tool. The majority of downregulated genes were enriched in cell cycle and DNA replication pathways (Supplementary Fig. 5 c). In contrast, upregulated genes were predominantly associated with adaptive and stress-related signaling pathways, including ERBB3 (PI3K-Akt signaling), eukaryotic translation initiation factor 2 alpha kinase 3 (EIF2AK3; ER stress response), PTEN-induced kinase 1 (PINK1; mitophagy), and Interferon Regulatory Factor 9 (IRF9; immune signaling)81–83 (Supplementary Fig. 5 c). While multiple transcripts involved in metabolism were significantly altered in the mouse dataset at lower SIM concentration, these effects were largely absent at 10 µM in human A375 cells, with only HMGCS1 and SLC25A1 remaining significantly modified (Supplementary Table 6—deposited in GEO under accession GSE329678). HMGCS1, a key enzyme in the cholesterol biosynthesis pathway, was consistently upregulated in both models, aligning with the expected feedback response to statin-mediated blockade of HMG-CoA reductase (Supplementary Table 1 and Supplementary Table 6—repository)84. In contrast, SLC25A1, which encodes the mitochondrial citrate transporter essential for supplying carbon for fatty acid and sterol synthesis, was significantly upregulated in mouse melanoma cells (3.5 µM SIM), but significantly downregulated in human A375 cells treated with a higher SIM concentration (10 µM) (Supplementary Table 1 and Supplementary Table 6—repository). Together, these results might suggest that while a SIM-induced feedback response in the cholesterol synthesis pathway (via HMGCS1) is conserved across mouse and human melanoma cells, the broader metabolic changes, particularly involving mitochondrial citrate export and downstream lipid biosynthesis (SLC25A1), may be modulated in a dose-dependent manner, with higher SIM concentrations in human cells leading to a reduction in some lipid synthesis-related processes or to no effect at all. This divergence suggests differential metabolic adaptation to SIM exposure, potentially reflecting differences in drug sensitivity or compensatory capacity. In our comparison, however, the low concentration of 3.5 µM used in the mouse B16.F10 experiments appears to engage early adaptive and survival signaling rather than terminal apoptotic responses, suggesting that the transcriptional signature of signaling pathways reflects concentration-dependent modulation. Gene set enrichment analysis (GSEA) revealed strong negative enrichment of key cell cycle pathways in SIM-treated A375 melanoma cells, namely HALLMARK_E2F_TARGETS and HALLMARK_G2M_CHECKPOINT (NES = − 2.76, q < 10⁻⁶) (Supplementary Fig. 5 d). These pathways regulate DNA replication and mitotic progression, and their coordinated suppression indicates inhibition of cell cycle progression. Given the central role of E2F-dependent transcription in regulating proliferation and the importance of G2/M checkpoint control for mitotic progression, these results indicate that SIM at 10 µM exerts a strong antiproliferative effect in human melanoma cells. This is consistent with the known mechanism of statins in disrupting mevalonate pathway-dependent signaling, leading to inhibition of cell growth and division7,84. Taken together, these analyses show that SIM induces both shared and species-dependent transcriptional changes in melanoma cells. In mouse cells treated with a lower SIM concentration, regulation was predominantly characterized by activation of metabolic and biosynthetic pathways. In contrast, human cells exposed to a higher SIM concentration exhibited stronger suppression of cell cycle and growth-related effects. Discussion The present work provides a follow‑up of our previous findings that inhibition of the constitutive expression of HIF‑1 in B16.F10 murine melanoma cells is one of the main actions behind the cytotoxicity caused by SIM on these aggressive cancer cells3,5,85. Our study provides novel mechanistic insights into the metabolic adaptations of B16.F10 murine melanoma cells under normoxia following SIM treatment, indicating that, SIM-induced reduction of HIF-1 and Akt levels exerted different effects on B16.F10 murine melanoma cell metabolism than those previously described under hypoxia10. These findings could be linked to lower intracellular levels of both regulatory factors under normoxic conditions compared to hypoxia5, which may result in distinct impacts on tumor metabolic pathways. At the same time, the contribution of HIF-1-independent mechanisms cannot be excluded, given the pleiotropic effects of SIM on multiple cellular processes. In this study, SIM was used at a concentration corresponding to the IC50 value, which was shown previously to inhibit B16.F10 melanoma cell proliferation by 50% without complete loss of cell viability3,5. As HIF-1 and Akt are essential regulators of cancer cell metabolism under hypoxia, and since the translation of subunit α of HIF-1 (HIF-1α) is tightly linked to Akt/mTOR signaling18,32,86–90, we also explored SIM effects on Akt mRNA and protein production in melanoma cells (Supplementary Table 1—repository, Fig. 1 and Supplementary Fig. 1). Our present results demonstrated that SIM-treated B16.F10 cells under normoxia displayed reduced Akt protein expression and increased Erk1 mRNA expression (p < 0.001), suggesting ERK1 signaling activation as an alternative rescue pathway81. These molecular changes are consistent with the established roles of Akt and HIF-1α in melanoma metabolic adaptation, although dedicated perturbation and rescue experiments will be required to establish direct causality. Further, we analyzed whether the energy and biosynthesis metabolic pathways of melanoma cells were affected by the changes induced by SIM in these regulatory proteins (Figs. 1, 2, 3, 4, 5, 6, 7). Our transcriptomic results might suggest that the inhibitory effects exerted by SIM on melanoma cell cholesterol metabolism91–93 were counteracted via upregulation of mRNA expression of genes encoding enzymes for isoprenoids production (Supplementary Table 1—repository and Supplementary Fig. 2) which would enhance cancer cell survival rates46–48. However, because statin treatments impair the synthesis of essential intermediates like isoprenoids94,95, cells can activate mitogen-activated protein kinase (MAPK) pathway as a stress response. MAPK signaling can modulate gene expression through overexpressed transcription factors such as c-Jun (Supplementary Table 1—repository), which can further enhance the transcription of genes of MVA pathway, as part of a stress-adaptive mechanism, in an attempt to compensate for the inhibition of the cholesterol intermediates biosynthesis in SIM-treated cells96,97. The observed upregulation of low-density lipoprotein receptor (Ldlr), Niemann-Pick disease type C1 and C2 (Npc1 and Npc2), along with the downregulation of ATP-binding cassette transporter A1 (Abca1) in SIM-treated cells, suggested an additional adaptive response to cholesterol depletion, supporting tumor cells progression (Supplementary Table 1—repository)98–101. With regard to glucose metabolism, the catalytic activities of PFK1 and LDH were decreased, but GLUT1 protein level was elevated in SIM-treated cells compared to control (Figs. 3 a,b, 4 a,b), indicating potential post-transcriptional regulation signaled through HIF-1-independent mechanisms 102–109 (Table 1 and Supplementary Table 4—repository). Despite increased G6PD mRNA levels, its catalytic activity was suppressed in SIM-treated cells (Table 1; Figs. 2,3,4 c), indicating reduced flux through PPP. Although STAT3 may transcriptionally regulate G6PD, this effect generally depends on STAT3 activation. Because p-STAT3 levels were not significantly altered following SIM treatment (Supplementary Fig. 4c), the mismatch between G6PD mRNA levels and enzymatic activity is unlikely to reflect STAT3-dependent transcriptional activation and may instead result from post-transcriptional and/or post-translational regulation of G6PD110–112, including impaired dimerization supported by Polo-like kinase 1 (Plk1) downregulation. (Supplementary Table 4—repository)110–114. Reduced glycolysis combined with increased GLUT1-mediated glucose uptake likely maintained mitochondrial pyruvate supply, while decreased PPP activity could be consistent with redistribution of glucose toward the hexosamine biosynthetic pathway (HBP), as supported by overexpression of GFAT1 and UGCG and enhanced UDP-GlcNAc–6 dependent glycosylation linked to cancer progression115–122. (Supplementary Table 1—repository). However, further investigations should be done to confirm these statements at the protein level. Restoration of TCA cycle activity in SIM-treated melanoma cells, was indicated by increased CS activity, as well as upregulation of IDH1, and enhanced mRNA expression of glutamine metabolism genes, suggesting glutamine-dependent anaplerosis under glycolytic inhibition (Supplementary Table 1—repository; Figs. 2, 3, 4, Table 1)58,123–125. Given the oncogenic role of mutant IDH1-derived 2-hydroxyglutarate126,127, together with reduced mt-ND1 levels and increased SLC25A1 mRNA expression, these results suggest that in SIM-treated cells, the TCA cycle may be preferentially used for biosynthetic functions rather than energy production, a hypothesis that requires further validation at the protein and metabolite levels (Table 1; Fig. 5 a,c). Also, additional protein-level validation is required to confirm if higher levels of ETC—Complex III and IV proteins are present, as suggested by the mRNA expression data (Table 1; Fig. 3 and Supplementary Fig. 3)128–135. In addition to the efflux of citrate via SLC25A1 from mitochondria to cytosol, SIM-treatment favored the transcription of lipolysis enzymes (such as, MAGL and ATGL) (Table 1 and Fig. 2)135–138, via accumulation of available FAs to support the synthesis of lipid-derived signaling molecules139. Previous studies proved that in hypoxia, Akt promotes FAs and lipid synthesis by favoring FASN and ACLY availability139,140. In normoxia, FASN expression was favored both at mRNA and protein level in SIM-treated group compared to the control (Table 1, Fig. 5 a,d), which may suggest high rates of FAS which could offer anti-apoptotic advantages to melanoma cells, contributing to chemoresistance73,141,142. In line with other studies, this dual demand for lipid (FA) synthesis and breakdown ensured that the cells maintain sufficient resources to sustain their growth and survival143. Under normoxic conditions, we did not observe the FASN-pAkt negative feedback reported in hypoxia (Fig. 1 a,c; Fig. 5 a,d), while increased expression of ACLY mRNA in SIM-treated cells supported enhanced citrate export from the TCA cycle for FAS (Table 1; Figs. 2–3). SIM-treatment also increased SCD1 and ELOVL expression promoting unsaturated FAS and FAE to limit lipid peroxidation and ER stress, but without a corresponding increase in mitochondrial or peroxisomal FAO despite reduced HIF-1α and pAkt levels (Table 1; Figs. 1, 2, 3, 5 a,e,f). Together, these findings suggest reduced energetic demand and a shift toward lipid remodeling, accompanied by increased prostaglandin synthesis, as indicated by elevated PGDS expression and prostaglandin D2 level (Supplementary Fig. 4 a), consistent with activation of inflammation-associated signaling pathways71,73,141,142,144–149. Moreover, in SIM-treated cells, increased expression of markers associated with lipid metabolism (FASN, SCD1, UFAs, PUFAs, PGDS) coincided with upregulation of multiple pro-tumorigenic and EMT-related genes, including STAT3, Rictor, Jun, Foxr2, Angptl2, Erbb3, Ahnak2, ATF3, and Ezr, alongside marked downregulation of the pro-apoptotic gene Bcl2-like 13 (Supplementary Table 4—repository). Together, these changes indicate an early adaptive response to SIM treatment linked to tumorigenesis52–62,89,90,150. Finally, to further evaluate the relevance of our findings in a human melanoma context, we complemented the B16.F10 RNAseq datasets, with functional in silico analyses in A375 human melanoma cells. The comparable antiproliferative response in A375 cells (Supplementary Fig. 5), together with the concordant regulation of key cell cycle-related genes (Supplementary Fig. 6, Supplementary Table 6—repository) noticed after the cross-species comparative analysis, strengthens the biological relevance of the observed suppression of cell cycle or the robustness of the SIM-induced growth-inhibitory phenotype across melanoma models151. In contrast, the metabolic responses were less uniformly conserved between mouse and human cells, suggesting that SIM-induced metabolic adaptation might be more strongly influenced by biological context and treatment conditions152. Conclusions Altogether, based on our data, showing enhanced lipid metabolism after SIM treatment, directed towards favoring UFAs accumulation and possible to isoprenoids and prostaglandin synthesis in B16.F10 cells, we suggest that this shift is consistent with an early adaptive response associated with SIM-induced survival and resistance-related traits. Although B16.F10 does not fully recapitulate the genetic landscape of human melanoma, it remains a well-established model for studying melanoma progression. Our findings should therefore be interpreted as mechanistic insights of SIM-induced metabolic adaptation in this experimental context (murine), rather than universal metabolic reprogramming across models. Importantly, the additional A375 functional data and cross-species transcriptomic comparison support both conserved and context-dependent effects of SIM in melanoma cells. While these results strengthen the relevance of some SIM-responsive effects in a human melanoma context, broader validation in additional human melanoma models and in more similar in vivo tumor microenvironment settings remains necessary. Nonetheless, our results identify lipid-associated metabolic pathways as promising candidate targets for further investigation and potential therapeutic exploitation in melanoma. Materials and methods Cell line and culture conditions B16.F10 murine melanoma cells (ATCC; CRL-6457; RRID: CVCL_0159) and A375 human melanoma cell line (ATCC CRL-1619IG-2; RRID: CVCL_IW10) were cultured in DMEM (Lonza Group, Basel, Switzerland CH) as a monolayer at 37 °C in 5% CO2 and 20% O2 atmosphere, as previously described3,153. B16.F10 melanoma cell line show key biological characteristics that resemble those seen in human melanoma cell lines, including drug-resistance and high metastatic potential, rapid proliferation, and the constitutive activation of critical signaling pathways such as the MAPK/ERK and PI3K/AKT, both of which also drive human melanoma progression154–156. SIM solutions SIM was purchased from Sigma-Aldrich Chemie GmbH, Germany. SIM IC50 (3.5 µM), as determined in our previous study was prepared from the stock solution of 24 mM SIM into the culture medium shortly before use3. Cells were incubated with 3.5 µM SIM for 24 h. RNA-seq B16.F10 cells were seeded as 1 × 106 cells/flask and treated with 3.5 µM SIM for 24 h at 37 °C. Then, the RNA isolation was performed using peqGOLD Total RNA isolation kit (PeqLab, Erlangen, DE), including the DNase digestion treatment of the lysates (peqGOLD DNase I Digest Kit, PeqLab, Erlangen, DE), to avoid DNA contamination, according to the manufacturer’s instructions157. The RNA was eluted with 50 μl of RNase-free water. The quantification of total RNA was performed by Invitrogen Qubit 4 Fluorometer (Thermo Scientific, MA, USA) with Broad Range (BR) Assay kit (Thermo Scientific, MA, USA), while RNA quality was determined using NanoDrop 1000 (Thermo Scientific, Ma, USA) according to the manufacturer’s protocol158. To remove rRNA from the total RNA Ribo-Zero rRNA removal beads (Illumina, Inc.) were used. Further, to generate strand-specific cDNA libraries, TruSeq Stranded Total RNA (Illumina, Inc.) was used followed by quality control procedure (Qubit 2.0 Fluorometer, Thermo Scientific, USA; Agilent 2100 bioanalyzer, Argilent Technologies, USA). The qualified libraries were then subjected to sequencing by high-throughput Illumina NovaSeq 6000 sequencing platform, PE 150 (Illumina, Inc.). Three biological replicates were used for each experimental group. Library construction and sequencing were performed by Novogene Corporation (UK). RNA-seq data analysis The clean obtained sequencing data were mapped to the mouse reference transcriptome by HISAT2 software (v2.0.5)159. For the estimation of transcript abundance of coding genes as Fragments Per Kilobase of transcript per Million mapped reads (FPKM), StringTie-eB software (v1.3.1)160 was used, then the differential expressed transcripts were identified by Ballgown package 2.22.0161,162. To measure the level of expression of each gene in SIM-treated group in comparison with its expression in control group, fold regulation (FR) values were calculated. Benjamini-Hochberg method was applied to adjust p-values for multiple testing163,164. Genes with a FR cutoff of ± 1.5, a p-value less than 0.05 and a false discovery rate (FDR) of 20% were considered differentially expressed165,166. Enrichment analysis of differentially expressed genes (DEGs) was performed using KEGG pathway and gene ontology (GO) annotation in the DAVID online tool (v2023q4)167,168. KEGG copyright permission was granted by Kanehisa Laboratories to publish the results of using KEGG and the KEGG-related images both in print and digital, under the CC BY 4.0 open access license49–51. Pathways with a p-value < 0.05 and an FDR < 0.2 were considered significant. The outcomes of DAVID were imported into R to generate the plots using ggplot2 library. Furthermore, pathway annotation of DEGs was performed in KEGG database, testing the statistical enrichment of mRNAs with KOBAS software (v.3.0). Venn diagram was done using Venny 2.1169, while the volcano plot was done in R using ggplot2 library. Hierarchical clustering of expression Z-scores of DEGs considered of interest was done in R, using heatmap.2 function. Z-scores were calculated for each row (each DEG) as follows, z = (x-μ)/σ, where x is the count value of the gene in a replicate, μ the mean of all count values of this gene in all replicates, and σ the corresponding standard deviation (SD)170. The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, version 12.0) was used to construct the protein-protein interaction (PPI) network from the DEGs dataset, with a high-confidence interaction score > 0.7. Significant primary clusters within PPI network were identified using the Markov Cluster Algorithm (MCL)171,172. Quantitative Real-Time PCR (RT-qPCR) RT-qPCR analysis was used to validate RNA-seq data. Total RNA (1 µg) for each group was reverse transcribed into cDNA, using iScriptTM Reverse transcription Supermix (#1,708,841, Bio-Rad Laboratories (Pacific) Pty Ltd, Gladesville, Australia) in a total volume of 20 µl. The complete reaction mix was incubated at 25 °C for 5 min for priming, followed by reverse transcription at 46 °C for 20 min and finally at 95 °C for 1 min for reverse transcriptase inactivation. Real-time quantitative PCR was performed using SsoFastTM EvaGreenR Supermix (#172–5200, Bio-Rad Laboratories (Pacific) Pty Ltd, Gladesville, Australia). cDNA (1 µl) was amplified with 500 mM specific primers. The primers sequences are mentioned in Table 2-Mendeley Data45 (purchased from Eurogentec, Seraing, Belgium). The following setup was used for the amplification: enzyme activation at 95 °C for 30 s, 40 cycles of denaturation at 95 °C for 5 min, and annealing at 55 °C for 5 s, followed by 65 °C-95°C for 5 s (in 0.5 °C inc). PCR and subsequent 1% agarose gel electrophoresis were used for validation of primer specificity (Supplementary Fig. 1—Mendeley Data45). All reactions were performed in CFX96TM Real-Time System (C1000 Touch Thermo Cycler, Bio-Rad Laboratories (Pacific) Pty Ltd, Gladesville, Australia) according to manufacturer’s instructions. Relative mRNA expression was quantified using the ΔΔCt method (Ct is threshold cycle) and normalized to β-actin mRNA as an internal control173. Cell lysates preparation Prior to inducing cell lysis, the B16.F10 cell monolayers were washed with PBS and the viable adherent cells were detached with Trypsin 1x (5 min incubation), then centrifuged at 260 × g for 5 min. Thereafter, the obtained pellets were resuspended in 250 μl lysis buffer as described previously174. The homogenates were kept on ice for 30 min, followed by centrifugation at 4 °C at 12 000 × g for 10 min. The supernatants were collected and stored at − 80 °C before further molecular measurements. Bradford assay was performed to determine the total protein concentration in the cell lysates (Sigma-Aldrich; Merck KGaA)3,174,175. As under normoxia HIF-1α has short half-life, this protein was stabilized in cell lysates using a lysis buffer containing cobalt chloride (1 mM)176. Moreover, to prevent rapid degradation in the presence of oxygen, all procedures were performed on ice as quickly as possible. Assessment of lactate dehydrogenase (LDH) activity To assess the LDH activity, the decrease of NADH absorbance at 340 nm was monitored in 10 μl of cell lysates. The variation of absorbance is directly proportional to the LDH activity, caused by conversion of NADH to NAD+, while lactate is transformed into pyruvic acid. The determination was performed using Jasco V-530 UV–VIS spectrophotometer, following the protocol described by Huijgen et al., 1997177,178. The values were represented as catalytic activity mU/mg protein. Three independent experiments were performed. Determination of PFK1 activity To test the activity of the glycolysis rate-limiting enzyme PFK1, Phosphofructokinase Assay Kit (Cat# MAK093, Sigma-Aldrich Chemie GmbH, Germany) was used. The principle of the assay is based on the coupled conversion of fructose-6-phosphate to fructose-1,6-diphosphate by the enzyme mix, resulting adenosine diphosphate (ADP) which is further converted to adenosine monophosphate (AMP) and NADH179. Then, NADH reduces a colorless probe, in a way dependent of the PFK activity. The obtained values were represented as miliunits (mU) of PFK1 activity/ml after measuring absorbance at 450 nm. Three independent experiments were performed. Glucose 6-phosphate dehydrogenase (G6PD) activity assay To evaluate G6PD activity, the first and rate-limiting enzyme of the PPP, 1 × 106 cells were homogenized in 100 μl ice-cold PBS, for each experimental group. The measurements were performed using G6PD activity assay kit (Cat# MAK015, Sigma-Aldrich Chemie GmbH, Germany) according to the supplier’s instructions. Thus, 20 μl of homogenate/sample was used. After the oxidation of glucose-6-phosphate by the enzyme mix, a colorimetric product was generated, and the intensity was monitored at 450 nm by a microplate reader (FLUOstar Omega (BMG, Labtech, Offenburg, Germany) in kinetic mode for 30 min. Catalytic activity in mU/ml had been used to express the results180. Three independent experiments were performed. Assessment of citrate synthase (CS) activity The investigation of activity of CS, the enzyme which catalyzes the synthesis of citrate from oxaloacetate in Krebs cycle, was performed by CS activity kit, (Cat# MAK193, Sigma-Aldrich Chemie GmbH, Germany), using 20 μl sample lysate/group. To quantify CS activity, the assay measures the color development of TNB chromophore (2-nitro-5-thiobenzoic acid), produced from Ellman’s Reagent, 5,5’-Dithiobis-2-Nitrobenzoic Acid (DTNB) and the CoA-SH generated during the citrate synthesis. The colorimetric product is directly proportional to the amount of active enzyme present in the samples181,182. The absorbance measurements at 412 nm were performed using a microplate reader (FLUOstar Omega (BMG, Labtech, Offenburg, Germany) in kinetic mode for 30 min. Each step was done according to the provider’s instructions. The enzyme’s activity was reported as mU/mL. Each sample was tested three times. Western blot analysis To assess the effect of the SIM on the expression of several critical protein players involved in the energy metabolism, western blot analysis was performed as described previously174,183. Different amounts of total protein were loaded for each protein immunoblotted, due to variations in the sensitivity and binding efficiency of the antibodies. We used a mix of polyclonal and monoclonal antibodies from different providers, each with different detection requirements. As a result, troubleshooting was needed to determine the appropriate protein loading for each protein of interest, to obtain detectable, clear and specific bands for each one. This step was essential to ensure consistent and reliable results across all experiments. Thus, to determine HIF-1α levels in cell lysates, 80 μg of total proteins from each lysate were loaded/per lane onto a 7.5% polyacrylamide gel. To reveal the expression of SCD1, 60 μg of total protein were used in each group, respectively 50 μg of total protein for acyl-Coenzyme A oxidase 3 (ACOX3) and mitochondrially encoded NADH dehydrogenase 1 (mt-ND1). To quantify FASN, we used 40 μg of total protein, while for facilitated glucose transporters, solute carrier family 2 member 1 (SLC2A1) / glucose transporter 1 (GLUT1), total protein kinase B (t-Akt) also known as serine/threonine-specific protein kinases and phosphorilated Akt (pAkt) 30 μg of total protein lysates were needed. To detect the levels of these proteins 10% polyacrylamide gel was used. Gel electrophoresis was conducted at 120 V for 1 h and 30 min. For protein transfer, a wet transfer was done at 100 V for 50 min to transfer proteins onto a polyvinylidene fluoride (PVDF) membrane. To block membranes, 5% skimmed milk powder dissolved in TBS-T (0.1% Tween) was used for 1 h at room temperature (Bio-Rad Laboratories, Inc., Hercules, CA, USA). Then, the membranes were immunoblotted overnight at 4 °C against the primary antibodies as follows, rabbit monoclonal IgG anti-mouse HIF-1α diluted 1:500 (Cat# ab179483, Abcam, Cambridge, United Kingdom), rabbit monoclonal IgG anti-mouse SCD1 1:500 (Cat# 2794, Cell Signaling, United States), rabbit polyclonal IgG anti-mouse ACOX3 1:1000 dilution (Cat# PA5-22,373, Pierce, Thermo Fisher Scientific, Inc.), rabbit polyclonal IgG anti-mouse mt-ND1 1:1000 (Cat# SAB5700797, Sigma-Aldrich Chemie GmbH, Germany), mouse monoclonal IgG anti-mouse FASN 1:1000 (Cat# sc-48357, Santa Cruz Biotechnology, Inc., United States), rabbit polyclonal IgG anti-mouse GLUT1 1:1000 (Cat# SAB4502803, Sigma-Aldrich Chemie GmbH, Germany), rabbit monoclonal IgG anti-mouse t-Akt 1:1000 (Cat# 4685, Cell Signaling, United States), rabbit polyclonal IgG anti-mouse p-Akt 1:1000 (Cat# sc-7985, Santa Cruz Biotechnology, Inc., United States), rabbit monoclonal antibody anti-mouse phospho-c-Jun (Cat#3270, Cell signaling, United States) and mouse monoclonal antibody phospho-STAT3 (Cat# bsm-33301, Bioss, United States). As primary antibody to test loading control, β-actin 1:1000 diluted rabbit polyclonal IgG anti-mouse β-actin (Cat# A2103, Merck, Darmstadt, GER) was used. As secondary antibodies, a goat anti-mouse horseradish peroxidase (HRP)-conjugated IgG (Cat# sc-2005, Santa Cruz Biotechnology, Inc., United States) was utilized for FASN detection, while goat anti-rabbit IgG HRP-conjugated was used to quantify HIF-1α, SCD1, ACOX3, mt-ND1, GLUT1, t-Akt and p-Akt (Cat# sc-2004, Santa Cruz Biotechnology, Inc., United States). Each secondary antibody was diluted 1:2500 in TBS-T and the membranes were incubated for 1 h at room temperature. Moreover, membranes were washed in TBS-T three times for 5 min before and after the incubation with the secondary antibody174,183. The detection was done using Clarity™ Western ECL Substrate (Bio-Rad) and the ChemiDocTM Imaging System (Bio-Rad, USA). The protein expression levels were identified by measuring the intensity of each lane on the membranes using Image Lab Software 4.1 (Bio-Rad). Densitometric and statistical analyses were performed using normalized target protein/β-actin ratios, which were then expressed relative to the control group. Data from at least two independent experiments were presented as mean ± SD. Wound healing assay Confluent monolayers of B16.F10 melanoma cells were grown in 24-well plates for 24 h184. Then, in each well a uniform scratch was made in cell monolayer using a sterile pipette tip as described previously184 . After the removal of the detached cells with PBS, fresh 2% fetal bovine serum DMEM medium was added to the control group, while the treated group received medium containing 3.5 µM SIM. Plates were incubated for 24 h under standard culture conditions3. Wound closure was assessed by capturing images at 0 and 24 h (magnification 50x) using a Zeiss Axio Vert.A1 inverted microscope (ZEISS). Cell migration was then quantified by analyzing the wound area using ImageJ software. The experiment was conducted with three biological replicates. Gelatin zymography The culture medium from each group was collected and centrifuged at 350 × g for 5 min to remove cell debris185. Bradford assay was used to detect the protein concentration in the supernatant175. The samples were mixed with non-reducing buffer containing 4% SDS, 20% glycerol, 0.01% bromophenol blue, 125 mM Tris–HCl, H₂O. Subsequently, 30 µg of protein per group was separated by SDS-PAGE under non-reducing conditions, using a 7.5% polyacrylamide separating gel containing 0.1% gelatin186,187. After electrophoresis, gels were washed to remove SDS and incubated overnight at 37 °C in incubation buffer. The next day, they were stained with Coomassie Blue and destained until clear bands of MMP gelatinolytic activity appeared. Enzyme activity was quantified by densitometry using Image Lab Software 4.1 (Bio-Rad)188. The experiment was conducted in duplicate. Quantitative determination of prostaglandin D₂ (PGD₂) Prostaglandin D₂ (PGD₂) levels in the two groups (SIM-treated cells and untreated cells) were quantified from the cell culture medium using a competitive enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s instructions (Cat# E1922Ge, EIAAB SCIENCE INC Ltd., Wuhan, China)189. The assay is based on the competitive binding of PGD₂ in samples with a biotin-labeled PGD₂ tracer for a limited number of antibody binding sites pre-coated on a microplate. Briefly, 50 µL of standards, blanks, and samples were added to each well, followed by the addition of Detection Reagent A. After incubation at 37 °C for 1 h, wells were washed three times with wash buffer. Detection Reagent B was then added and incubated for 45 min at 37 °C, followed by five washing steps. Subsequently, substrate solution was added and incubated at 37 °C for 20 min protected from light. The reaction was stopped using stop solution, and optical density was measured immediately at 450 nm using a microplate reader. Three biological replicates were tested, and concentrations were presented as mean ± SD. Cell proliferation assay Cell proliferation using A375 human melanoma cells was evaluated following SIM treatment using BrdU ELISA colorimetric immunoassay (Roche Applied Science) according to the manufacturer’s4,190. Briefly, 1000 A375 human melanoma cells per well were seeded in 96-well plates and allowed to attach for 24 h. Cells were then treated with SIM at concentrations ranging from 1.2 to 239 µM (in triplicate), while cells cultured in medium alone served as controls. The assay is based on the incorporation of the thymidine analogue bromodeoxyuridine (BrdU) into newly synthesized DNA of proliferating cells. After 24 h incubation with BrdU, the culture medium was removed, and the cells were fixed and the DNA denatured. A peroxidase-conjugated monoclonal anti-BrdU antibody (anti-BrdU-POD) was added to detect incorporated BrdU. Following 1 h incubation, the antibody solution was removed, and the wells were washed three times with PBS. Tetramethylbenzidine substrate was then added, and the reaction product was quantified by measuring absorbance at 450 nm with a reference wavelength of 655 nm. Results were expressed as the percentage of proliferation inhibition relative to the control. Data are presented as mean ± SD (n = 3). In silico comparison of SIM transcriptional response between mouse and human melanoma cells To assess the cross-species concordance of the SIM transcriptional response, we compared our mouse RNA-seq data with human transcriptional profiles from the Library of Integrated Network-Based Cellular Signatures (LINCS) L1000 dataset obtained from the CLUE platform (https://clue.io/releases/data-dashboard)191. Specifically, we extracted level 5 consensus perturbational profiles (moderated z-scores, MODZ) for SIM-treated human melanoma cell lines from the compound treatment dataset (level5_beta_trt_cp_n720216 × 12,328.gctx). For each gene, the median log2 fold change across transcripts was computed as the effect size estimate, using a pseudo count of 1 to handle zero expression values (log2((SIM + 1) / (CONTROL + 1))). The FDR was assigned from the transcript exhibiting the largest absolute log2 fold change, representing the most strongly responding isoform. Mouse gene symbols were mapped to human orthologs using Ensembl BioMart via the biomaRt R package retrieving MGI symbol, mouse Ensembl gene ID, human Ensembl gene ID, and human HGNC symbol for each gene192,193. Genes without a human ortholog annotation were excluded. Transcriptional concordance between the mouse B16.F10 log2 fold changes and the human A375 LINCS z-scores was assessed using Spearman rank correlation194, which is appropriate given the different scales and distributions of the two measures194. Correlation and associated p-values were computed using the stats package in R195. Analysis was performed both across all genes with available ortholog mappings and within the subset of statistically significant mouse DEG (FDR < 0.05). The A375 human melanoma cell line treated with 10 µM SIM for 24 h (sample identifier: CPC005_A375_24H:BRD-A81772229-001–01-6:10) (A375, 10 µM, 24 h) was used as the primary comparison, corresponding most closely to our mouse experimental conditions (B16.F10, 3.5 µM, 24 h). Directional concordance was visualized by classifying genes into four categories based on the sign of their log2 fold change and LINCS z-score: both upregulated, both downregulated, mouse up/human down, and mouse down/human up. The top 20 concordantly regulated genes by absolute log2 fold change are reported. All analyses and visualizations were performed in R using the cmapR, biomaRt, dply, tidyr, ggplot2, and patchwork packages192,196–200. The association between effect direction in mouse and human was evaluated using Fisher’s exact test applied to a 2 × 2 contingency table with a two-sided alternative hypothesis. Statistical analyses were performed in GraphPad Prism (GraphPad Software, San Diego, CA, USA), and p-values < 0.05 were considered statistically significant. DAVID online tool (v2023q4) was used to identify associated pathways and functional categories. To identify biological pathways enriched among SIM-regulated genes in A375 human cell line, Gene Set Enrichment Analysis (GSEA) was performed using the clusterProfiler R package201 against the Hallmark gene set collection from the Molecular Signatures Database (MSigDB202), retrieved using the msigdbr package203. Statistically significant differentially expressed genes (FDR < 0.05) were ranked by log2 fold change in descending order. Mouse gene symbols were converted to Entrez IDs using the clusterProfiler function bitr with the org.Mm.eg.db annotation database204. GSEA was performed using the ranked Entrez ID list against mouse Hallmark gene sets, with a minimum gene set size of 15, maximum of 500. Statistical analysis Mean ± SD was used to report data obtained from different experiments. Unpaired Student’s t-test was used to statistically compare the effects of SIM-treatment on different enzymes activities /protein expression levels with those from untreated cell lysates. GraphPad Prism version 7 for Windows (San Diego, CA, USA) was used to conduct all statistical analyses. A p-value lower than 0.05 was defined as significant. Supplementary Information Supplementary Information 1. Supplementary Information 2. Supplementary Information 1. Supplementary Information 2.